Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)

10. november 2026 oppdatert av: Jonathan Greenberg, Massachusetts General Hospital

The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

260

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 35 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Sustained a concussion 3-10 weeks earlier
  2. At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
  3. Age 18-35
  4. English fluency and literacy
  5. Ability and willingness to participate in study procedures, assessments, and intervention
  6. Access to a smartphone or computer with internet access
  7. Cleared for participation by clinic/study staff

Exclusion Criteria:

  1. Participation in mind-body or CBT treatment in the past 3 months
  2. Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
  3. Practice of mindfulness techniques > 45 minutes/week in the past 3 months
  4. Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
  5. Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
  6. Pregnancy
  7. Serious comorbidity expected to worsen in the next 6 months
  8. Secondary gains that may bias motivation (e.g., pending disability claim)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Toolkit for Optimal Recovery after Concussion (TOR-C)

A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills.

TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation.

Aktiv komparator: Health Enhancement after Concussion (HE-C)

A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion

HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Post-Concussion Symptom Scale (PCSS)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Generalized Anxiety Disorder scale (GAD-7)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.)

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the severity of depression symptoms.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Symptom Catastrophizing Scale
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them).

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Measures the tendency to limit or avoid various activities in response to medical conditions

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
Pittsburgh Sleep Quality Index (PSQI)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

An exploratory outcome which measures sleep quality over the past month.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
PROMIS Cognitive Function
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking).

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Tidsramme: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability.

Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juni 2027

Primær fullføring (Antatt)

1. desember 2030

Studiet fullført (Antatt)

1. desember 2030

Datoer for studieregistrering

Først innsendt

29. oktober 2026

Først innsendt som oppfylte QC-kriteriene

29. oktober 2026

Først lagt ut (Faktiske)

9. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026P002591

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"

IPD-delingstidsramme

Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period

Tilgangskriterier for IPD-deling

Interested parties can create an account in the Vivli Database and submit a request to access study data

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .